

1 **Full title:** High confidence and demand for hepatitis E vaccine during an outbreak in Bentiu,  
2 South Sudan: A qualitative study

3  
4 **Short title:** High confidence and demand for hepatitis E vaccine in Bentiu, South Sudan

5  
6 Aybüke Koyuncu<sup>1,2\*</sup>, Kinya Vincent Asilaza<sup>3</sup>, John Rumunu<sup>4</sup>, Joseph Wamala<sup>6</sup>, Priscillah Gitahi<sup>3</sup>,  
7 Zelie Antier<sup>3</sup>, Jetske Duncker<sup>3</sup>, Patrick Nkemenang<sup>3</sup>, Primitivo Gakima<sup>5</sup>, Melat Haile<sup>5</sup>, Etienne  
8 Gignoux<sup>2,5</sup>, Manuel Albela<sup>5</sup>, Frederick Beden Loro<sup>6</sup>, Duol Biem<sup>4</sup>, Monica Rull<sup>5</sup>, Andrew S  
9 Azman<sup>1,5,7,8</sup>, Iza Ciglenecki<sup>5</sup>, Robin Nesbitt<sup>2</sup>

10  
11 <sup>1</sup>Johns Hopkins University, USA

12 <sup>2</sup>Epicentre, France

13 <sup>3</sup>Médecins Sans Frontières, South Sudan

14 <sup>4</sup>Ministry of Health, South Sudan

15 <sup>5</sup>Médecins Sans Frontières, Switzerland

16 <sup>6</sup>World Health Organisation, South Sudan

17 <sup>7</sup>Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva,

18 Switzerland

19 <sup>8</sup>Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva,

20 Switzerland

21

22 \*Corresponding author

23 Email: akoyunc1@jhu.edu

24

25

## 26 **Abstract**

27 **Introduction:** In 2021 in response to an outbreak of hepatitis E in Bentiu internally  
28 displaced persons camp the South Sudanese Ministry of Health with support from Médecins  
29 Sans Frontières implemented the first-ever mass reactive vaccination campaign with HEV239  
30 (Hecolin; Innovax, Xiamen, China). As part of an evaluation of the feasibility of hepatitis  
31 vaccination as part of an epidemic response, we conducted qualitative research to assess  
32 knowledge, attitudes, and practices related to hepatitis E and the hepatitis E vaccine.

33 **Methods:** We conducted 8 focus group discussions (FGDs) with community leaders, the  
34 general population of vaccine-eligible adults, vaccine-eligible pregnant women (vaccinated and  
35 non-vaccinated), and healthcare workers. FGDs were separate by gender and were audio  
36 recorded, transcribed, and translated to English by trained research assistants. Two coders  
37 used inductive thematic analysis to organize emergent themes.

38 **Results:** Data were collected in November 2022. Most individuals had personal  
39 experiences with hepatitis E. Hepatitis E was perceived as a dangerous disease, and almost  
40 everyone was knowledgeable about transmission pathways. Participants believed children,  
41 pregnant women, and the elderly were the highest risk groups. Participants frequently made  
42 requests for additional hepatitis E vaccination campaigns and expanded eligibility criteria for  
43 vaccination. The primary barriers to vaccination were practical issues related to being away  
44 from the camp at the time of the campaign, but participants shared that some in the community  
45 were unvaccinated due to fears about injections, social pressure, misinformation about side  
46 effects such as infertility, concerns about why some groups were eligible for vaccination and not  
47 others (e.g. young children), and a lack of information about the vaccine/vaccination campaigns.

48 **Conclusion:** Personal experiences with hepatitis E illness, perceived severity of illness,  
49 and confidence in organizations recommending the vaccine were drivers of high demand for  
50 hepatitis E vaccines in the first-ever use of the vaccine in an outbreak setting.

51

52

53

54

55

56

## 57 **Introduction**

58

59 Hepatitis E genotypes 1 and 2 cause over 3 million symptomatic cases of acute viral hepatitis  
60 each year with case fatality risk as high as 65% among pregnant women [1–3]. Large outbreaks  
61 of hepatitis E virus (HEV) genotypes 1 and 2 occur due to fecal contamination of drinking water,  
62 and at least 1 large-scale outbreak with over 5,000 suspected hepatitis E cases has occurred in  
63 every decade since 1988 [4]. While outbreaks occur in resource-limited settings throughout  
64 Africa and Asia, refugees and internally displaced persons are at heightened risk for outbreaks  
65 due to overcrowding and poor access to safe water, sanitation, and hygiene (WASH) [1,5].

66

67 One potential tool for HEV outbreak control is a recombinant vaccine, HEV239 (Hecolin;  
68 Innovax, Xiamen, China), which has been proven to be safe and efficacious in individuals 16-64

69 years old [6]. The vaccine is licensed only in China and Pakistan and has not been  
70 recommended by the World Health Organization (WHO) for routine use in HEV-endemic  
71 countries, largely due to a lack of epidemiologic data in the general population [1]. Despite a  
72 lack of data to justify routine use of the vaccine, in 2015 WHO recommended the vaccine be  
73 considered as a strategy to mitigate or prevent outbreaks [1]. While the current vaccine's 3-dose  
74 schedule given across 6 months is not ideal for rapid deployment in outbreak settings [7],  
75 multiyear protracted HEV epidemics suggest the potential for even a 6-month regimen to  
76 substantially prevent morbidity and mortality, particularly among high-risk groups such as  
77 refugees and pregnant women.

78  
79 In Bentiu IDP camp, hepatitis E cases have been reported since 2014 with large outbreaks  
80 occurring in 2015-2016 and again in 2019. Between October 2014 and April 2022 there were  
81 2,227 confirmed cases of hepatitis E in Bentiu camp. In response, the South Sudanese Ministry  
82 of Health (MOH) in partnership with MSF implemented the first-ever vaccination campaign for  
83 hepatitis E in the context of an outbreak beginning in March 2022. The campaign targeted  
84 individuals 16-40 years old residing in Bentiu camp, including pregnant women. The campaign  
85 took place in three rounds in March, April and October 2022 [8]. In parallel, MOH and MSF  
86 implemented operational research to understand the effectiveness, safety, and feasibility of  
87 vaccination against hepatitis E. As part of this research, a vaccination coverage survey was  
88 conducted immediately after the third and final vaccination round. Coverage with at least one  
89 dose of the vaccine in the target population was 86% (95% CI: 84-88), and the most frequent  
90 reasons for non-vaccination were physical absence (60%) and fears and concerns (18%) [9].  
91 Here we report findings from the qualitative component of the study aimed at understanding  
92 community perspectives on hepatitis E, hepatitis E vaccine, and barriers and facilitators of  
93 vaccine uptake.

94

95

## 96 **Materials and methods**

97

### 98 **Setting**

99 Bentiu internally displaced persons (IDP) camp was established in 2014 as a Protection of  
100 Civilians site at a United Nations Mission in South Sudan base in response to conflict in Unity  
101 State. The camp has expanded since 2014 and the total camp population in 2022 was  
102 approximately 112,000 residents.

103

### 104 **Participants**

105 We recruited community leaders, the general population of vaccine-eligible adults(i.e. 16-40  
106 years, resident of Bentiu IDP camp), vaccine-eligible pregnant women (vaccinated and non-  
107 vaccinated), and healthcare workers to participate in focus group discussions (FGDs). The  
108 general population was recruited using convenience sampling in each camp sector from  
109 individuals already participating in research on vaccine coverage while pregnant women were  
110 recruited from individuals already participating in research on vaccine safety. Community  
111 leaders and medical staff were approached separately for recruitment. We asked the Camp  
112 High Commission to recommend community leaders and asked managers at health facilities to  
113 recommend medical staff working with hepatitis E patients.

114

### 115 **Data collection**

116 Data were collected in November 2022. We selected the Behavioral and Social Drivers of  
117 Vaccination (BeSD) framework [10] *a priori* to develop FGD guides and organize emerging

118 themes for knowledge, attitudes, and practices about hepatitis E, perceptions about the hepatitis  
119 E vaccine, and barriers and facilitators of hepatitis E vaccine uptake. The BeSD framework is a  
120 theory-based framework for understanding individual and community-level drivers of vaccination  
121 uptake that is organized into four domains: thinking and feeling, social processes, motivation,  
122 and practical issues (Fig 1).

123  
124 **Figure 1** The behavioral and social drivers of vaccination (BeSD) framework. Based on the BeSD working group (10) and adapted  
125 from Brewer et al. [11]

126  
127 FGDs were conducted separately by population type and gender except for healthcare workers.  
128 FGDs were conducted in Nuer or English and were audio recorded, transcribed, and translated  
129 to English.

130

## 131 **Analysis**

132 Within domains of the BeSD framework, two coders (AK and RN) used inductive thematic  
133 analysis to iteratively read transcripts and code the text in the data. Emergent key themes and  
134 codes were entered into a codebook, and codebooks and the categorization of data were  
135 compared for 2 FGDs. We used a negotiated agreement approach to assess intercoder  
136 reliability [12], with differences in coding adjudicated by discussion and consensus between  
137 coders. Once the emergent codes and themes were standardized, both coders independently  
138 coded the text in the remaining data using Nvivo software (QSR International, Melbourne,  
139 Australia). Once the emergent codes and themes were standardized, both coders independently  
140 coded the text in the remaining data using Nvivo software (QSR International, Melbourne,  
141 Australia).

142

143

## 144 **Ethics**

145 Ethical approval was granted from the MSF Ethical Review Board (ERB) and by the South  
146 Sudan Ministry of Health Research Ethics Board as part of the study protocol titled:  
147 “Effectiveness, safety and feasibility of recombinant hepatitis E vaccine HEV 239 (Hecolin)  
148 during an outbreak of hepatitis E in Bentiu, South Sudan” (MSF ERB #2167 and RERB-MOH #  
149 54/27/09/2022). All participants provided verbal informed consent before participating in a FGD.

150

## 151 **Results**

152 We conducted 8 FGDs with 6-8 participants each (48-64 total participants): 2 FGDs with  
153 community leaders, 2 FGDs with the vaccinated general population, 2 FGDs with the  
154 unvaccinated general population, 1 FGD with healthcare workers, and 1 FGD with pregnant  
155 women. Participants from the general population were aged 18-40 while community leaders and  
156 healthcare workers included participants outside of the vaccine-eligible range. Emergent themes  
157 were consistent by participant type and gender.

158

## 159 **Thinking and feeling**

160 All population types were very knowledgeable about hepatitis E symptoms, transmission  
161 pathways, and prevention methods. The most frequently mentioned symptoms associated with  
162 hepatitis E were yellow eyes, fever, and dark urine. Some participants also mentioned yellow or  
163 “light” skin and general weakness of the body. Cleanliness and WASH were frequently reported  
164 as key prevention strategies. Many respondents felt it was difficult to prevent HEV infection with  
165 vaccine alone because of the crowded conditions in the camp:

166

167 *“All toilets are full and we are trying to advice people to be vaccinated yet the problem of toilets*  
168 *is very dangerous one.”* *-Male community leader*

169

170 Most participants had high perceived risk of being infected with hepatitis E and perceived  
171 hepatitis E as a dangerous and serious infection. Hepatitis E was perceived as more severe in  
172 comparison to other infectious diseases such as malaria:

173

174 *“HEP E is dangerous compared with malaria; malaria can be treated but HEP E can take long to*  
175 *be treated.”* *-Male community leader*

176

177 Other reasons for perceiving hepatitis E as more serious compared to other infections included  
178 potential impacts of infection on family finances (e.g if the breadwinner is infected), the potential  
179 for infection to be fatal, and knowledge that there is no existing treatment. Many individuals  
180 described traditional healing methods for hepatitis E that were used in their villages and also in  
181 the camp which involve beating the infected person with a hot metallic stick.

182

183 *“During the village life, when you are HEP E positive, the only thing people do is beat you with*  
184 *metallic stick put on fire for you to get well, but now we have the vaccine given by MSF freely*  
185 *without paying any single money. when you are beaten with that thing put on fire, you will feel*  
186 *pain at the same time.”*

187 *-Pregnant female community member*

188

189 Most individuals had personal experiences with hepatitis E including being infected themselves  
190 or having a family member, neighbor, or community member that had been symptomatically  
191 infected:

192



193 *“In the past, during the time of village life, my sister was infected with HEP E, because there*  
194 *were no vaccine, she died, but now the vaccine is brought by MSF...”*

195 *-Pregnant female community member*

196

197 *“Community leaders like the vaccine because they have seen the how worse is HEP E in the*  
198 *past and it infected some of them, some of them were involved during the campaign too.”*

199 *-Female community leader*

200

201 Children, pregnant women, and the elderly were consistently identified as high-risk groups for  
202 HEV infection and/or severe outcomes. Children were perceived as being at high-risk because  
203 they play in dirty areas in the camp, are more likely to practice open defecation and don't know  
204 how to take care of themselves, have weak immune systems, and because they forget  
205 instructions from parents (e.g. to not play in dirty areas) and can't communicate symptoms when  
206 they are ill. Many participants questioned the eligibility criteria for vaccination and requested that  
207 future campaigns include children and elderly in the target population:

208

209 *“In this camp, many people are infected, but mostly children. My question is that, why MSF is*  
210 *not bring the vaccine for children? And this disease is affecting children serious through dirty*  
211 *water and dirty playing in dirty environment.”*

212 *-Male community leader*

213

214 Participants were aware of the risk of severe outcomes among pregnant women, and the elderly  
215 were perceived as a high-risk group for severe outcomes due to weakened immune systems.

216

217 *“When this disease infect the pregnant mother, its not easy for such a mother to survived.”*

218 *-Healthcare worker*

219

220 Participants had high confidence in vaccine effectiveness and benefits, vaccine safety, and the  
221 organizations recommending the vaccine. Most participants believed it was safe for women to  
222 receive the vaccine during pregnancy, though some unvaccinated males acknowledged not  
223 knowing if the vaccine was safe for pregnant women. Many participants reported positive  
224 impacts of the vaccine campaign such as a perceived reduction in the incidence of hepatitis E.  
225 Participants mentioned some community members refused the vaccine due to low knowledge  
226 about the importance of the vaccine and rumors about vaccine safety circulating in the  
227 community (e.g. fears about infertility following vaccination), but did not report being personally  
228 concerned about benefits, safety, or side effects. Some participants reported mild side effects  
229 after vaccination such as headaches or fever that cleared in a few days. Some vaccinated  
230 individuals reported fear of injections as a personal barrier to vaccination that they overcame.  
231 Others mentioned concerns about eligibility as a reason for non-vaccination among community  
232 members:

233 *“Some people refused the vaccine because they said that why MSF is vaccinating some group*  
234 *and leave others to be killed by the disease? Some refused for that reason.”*

235 *-Male community leader*

## 236 **Social processes**

237 Most individuals were in support of vaccination and had been vaccinated. Individuals in the  
238 general population perceived that most of their community and religious leaders were in support  
239 of vaccination, and had high respect for healthcare workers recommending and providing  
240 vaccines:

241

242 *“We trust also the people who offered to us the vaccine because they are the members of this*  
243 *community”*

244 *-Vaccinated female community member*

245  
246 Trusted relationships with vaccinators and organizations promoting the vaccine were influential  
247 in the decision to get vaccinated. Participants reported trusting the vaccine and vaccinators  
248 because the vaccine was brought by doctors, the vaccine was brought by MSF, and because  
249 the government permitted the vaccination campaign:

250  
251 *“As other people talk about it before, this vaccine is very saved for the community because it*  
252 *was brought by doctors from MSF, if we get it from other sources, we will never trust the vaccine*  
253 *at all, if bush men come and tell us about this vaccine, we will never accepted to be vaccinated.”*

254 *-Female community leader*

255  
256 Though decision-making was not mentioned explicitly in all FGDs, some participants mentioned  
257 the final person to tell whether family members should be vaccinated or not was either the father  
258 or mother of the family. Some participants mentioned pressure from other community members  
259 to refuse vaccination and circulating rumors about side effects such as infertility and an  
260 increased risk of getting other diseases.

261

## 262 **Motivation**

263 Individuals were highly motivated to get vaccinated. There were frequent requests for additional  
264 hepatitis E vaccination campaigns in the future and expanded age and geographic eligibility in  
265 future campaigns:

266

267 *“My question is about those who are living outside the camp, is there any mean for this to get*  
268 *the vaccine? Remember these people are part of this community.”*

269 *-Male community leader*

270

## 271 **Practical issues**

272 Key facilitators of vaccination were that the vaccine was available free of charge and that  
273 vaccinators went to all areas of the camp. The primary barrier to vaccination among  
274 unvaccinated adults was being away from the camp at the time of the campaign:

275

276 *“I was not vaccinated because I was far away from the camp during the vaccination, so I was*  
277 *unlucky, my appeal to MSF is if there is still vaccine remain, we should be considered.”*

278 *-Unvaccinated female community member*

279

280 Some participants also reported a lack of information about the vaccine and the second and  
281 third rounds of the vaccination campaign as a barrier to vaccine uptake.

282

## 283 **Discussion**

284 Our study identified high demand for hepatitis E vaccines among residents of Bentiu IDP camp,  
285 following the first-ever use of the vaccine in an outbreak setting. Personal experiences with  
286 hepatitis E illness, the perceived severity of illness, and high confidence in the healthcare  
287 providers and organizations recommending and providing the vaccine were key facilitators of  
288 vaccine uptake. Perceptions about hepatitis E and the hepatitis E vaccine in our study were  
289 consistent by vaccination status, gender, and population type, with the consistency of key  
290 themes suggesting data saturation. For example, even unvaccinated adults in our study  
291 reported predominantly positive perceptions about the vaccine and asked for additional

292 opportunities to be vaccinated. While improvements to comprehensive WASH infrastructure are  
293 needed for long-term control of hepatitis E and other pathogens as noted by community  
294 members, we identified high demand for hepatitis E vaccines as a tool for prevention and  
295 control of hepatitis E outbreaks.

296  
297 During the second and third rounds of the campaign, the vaccine was offered to anyone within  
298 the target group (16-40 years old and residence in Bentiu IDP camp), regardless of whether  
299 they received previous doses or not (8). The campaign also had a longer duration than most  
300 reactive vaccination campaigns: each round of the campaign lasted more than a week, and the  
301 final round lasted more than 2 weeks. Despite these attempts to improve vaccine access, the  
302 primary self-reported barrier to vaccine uptake was being away from the camp at the time of the  
303 campaign. Our qualitative findings are consistent with the quantitative coverage survey  
304 conducted in Bentiu and with findings about primary reasons for non-vaccination in preventative  
305 and reactive vaccination campaigns with oral cholera vaccines in various settings [13–15]. The  
306 population in Bentiu IDP camp, like many other camp settings, is highly mobile and spends long  
307 periods of time outside of the camp. Expanding access to vaccines beyond short-duration  
308 campaigns can improve vaccine uptake and increase the likelihood of sustainably maintaining  
309 coverage in highly mobile populations such as IDPs. Additional research is needed to explore  
310 the potential costs and benefits of vaccination strategies such as extending the duration of the  
311 campaign, offering the vaccine to all new camp entries, or routinely offering the vaccine in  
312 health facilities. The possibility of implementing these strategies for hepatitis E vaccine is further  
313 complicated by Hecolin's bulky, single-dose, pre-filled glass syringes which introduce additional  
314 challenges for transport, storage, and waste management.

315  
316 Children and the elderly were consistently identified as high-risk groups for HEV infection and  
317 severe outcomes by the community in Bentiu but were ineligible for vaccination in the campaign.

318 For some individuals, the exclusion of children and the elderly from the campaign contributed to  
319 vaccine refusal for themselves. The age target for the campaign (16-40 years) was chosen  
320 because the vaccine is not currently registered for use in children younger than 16 years and  
321 due to limited doses of the vaccine the upper limit was chosen based on the lower attack rate  
322 for hepatitis E among older adults in the camp (8). Notably, perceptions about children as a  
323 high-risk group for infection are mirrored in surveillance data on hepatitis E in the camp (68% of  
324 confirmed hepatitis E cases based on rapid diagnostic tests between October 2014 and April  
325 2022 were aged 10 years or younger (unpublished data)). Additional research is needed to  
326 understand the role of children in HEV outbreaks, the safety and efficacy of the vaccine in  
327 children, and the potential value of expanding age-eligibility for the vaccine.

328  
329 Even amongst unvaccinated participants, we identified few participants with negative views  
330 about the vaccine. This may be because the primary barrier to vaccination was being away from  
331 the camp. Though not mentioned explicitly by participants in our study, it is also possible that  
332 individuals who previously refused the vaccine may have changed their views after witnessing  
333 the safety and benefits of the vaccine in their community. Individuals who agreed to participate  
334 in this study also may have been more likely to have positive views about the vaccine compared  
335 to the general population in Bentiu, and may have been more likely to report positive views  
336 during FGDs due to social desirability bias. In an effort to reduce social desirability bias we  
337 asked participants to share community perceptions in addition to personal perceptions. Our  
338 findings are also consistent with anecdotal data from staff involved in the vaccination campaign  
339 as well as results from the coverage assessment which demonstrated high uptake of the  
340 vaccine (9). Studies on the acceptability of hepatitis E vaccines are limited, and vaccine  
341 confidence can depend on disease-specific knowledge, attitudes, and practices. However, our  
342 findings that perceived severity of hepatitis E was a key facilitator for high vaccine confidence  
343 and uptake are consistent with qualitative findings from Juba, South Sudan examining drivers of

344 high oral cholera vaccine uptake during a humanitarian crisis [16]. Our findings may not be  
345 generalizable to outbreak settings with limited historical outbreaks of hepatitis E or to settings  
346 where trusted relationships with MSF and/or the government are lacking. However, our findings  
347 underscore the importance of building trust with communities before, during, and after outbreaks  
348 as a strategy for building vaccine confidence.

349

## 350 **Conclusion**

351 Hepatitis E is a known and feared disease among the population, and vaccination against it was  
352 a widely accepted and sought-after method of preventing it. Cultivating trusted relationships with  
353 communities over time can help individuals overcome common barriers to vaccine confidence.  
354 Addressing practical issues related to being away from the camp at the time of the campaign  
355 can improve coverage in future campaigns.

356

## 357 **Acknowledgments**

358 We would like to thank the MSF hepatitis E vaccination and hospital study teams in Bentiu for  
359 their support in implementing the campaign and operational research, as well as the study  
360 participants for sharing their perspectives and experiences.

361

## 362 **References**

363

- 364 1. World Health Organization. Hepatitis E vaccine: WHO position Paper. 2015 pp. 185–200.
- 365 2. Kamar N, Bendall R, Legrand-Abravanel F, Xia N-S, Ijaz S, Izopet J, et al. Hepatitis E. The  
366 Lancet. 2012;379: 2477–2488. doi:10.1016/S0140-6736(11)61849-7


- 367 3. Amany G, Kizito S, Nabukenya I, Kalyango J, Atuheire C, Nansumba H, et al. Risk  
368 factors, person, place and time characteristics associated with Hepatitis E Virus outbreak  
369 in Napak District, Uganda. *BMC Infect Dis.* 2017;17. doi:10.1186/s12879-017-2542-2
- 370 4. Koyuncu A, Mapemba D, Ciglenecki I, Gurley ES, Azman AS. Setting a Course for  
371 Preventing Hepatitis E in Low and Lower-Middle-Income Countries: A Systematic Review  
372 of Burden and Risk Factors. *Open Forum Infectious Diseases.* 2021;8: ofab178.  
373 doi:10.1093/ofid/ofab178
- 374 5. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of  
375 hepatitis E virus genotypes 1 and 2 in 2005. *Hepatology.* 2012;55: 988–997.  
376 doi:10.1002/hep.25505
- 377 6. Zhu F-C, Zhang J, Zhang X-F, Zhou C, Wang Z-Z, Huang S-J, et al. Efficacy and safety of  
378 a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-  
379 blind placebo-controlled, phase 3 trial. *Lancet.* 2010;376: 895–902. doi:10.1016/S0140-  
380 6736(10)61030-6
- 381 7. Azman A.S., Bouhenia M., Iyer A.S., Rumunu J., Deng L.L., Wamala J.F., et al. High  
382 hepatitis e seroprevalence among displaced persons in south sudan: Evidence of  
383 undetected transmission and implications for vaccination. *American Journal of Tropical  
384 Medicine and Hygiene.* 2016;95: 593. doi:10.4269/ajtmh.abstract2016
- 385 8. Ciglenecki I, Rumunu J, Wamala JF, Nkemenang P, Duncker J, Nesbitt R, et al. The first  
386 reactive vaccination campaign against hepatitis E. *The Lancet Infectious Diseases.*  
387 2022;22: 1110–1111. doi:10.1016/S1473-3099(22)00421-2
- 388 9. Nesbitt RC, Asilaza VK, Gignoux E, Koyuncu A, Gitahi P, Nkemenang P, et al. Vaccination  
389 coverage and adverse events following a reactive vaccination campaign against hepatitis E



- 390 in Bentiu displaced persons camp, South Sudan. *PLoS Negl Trop Dis*. 2024;18: e0011661.  
391 doi:10.1371/journal.pntd.0011661
- 392 10. Behavioral and Social Drivers of Vaccination (BeSD) - The Vaccination Demand Hub. 7 Jul  
393 2022 [cited 1 Jun 2023]. Available: [https://demandhub.org/behavioral-and-social-drivers-of-](https://demandhub.org/behavioral-and-social-drivers-of-vaccination-besd/)  
394 [vaccination-besd/](https://demandhub.org/behavioral-and-social-drivers-of-vaccination-besd/)
- 395 11. Brewer NT, Chapman GB, Rothman AJ, Leask J, Kempe A. Increasing Vaccination:  
396 Putting Psychological Science Into Action. *Psychol Sci Public Interest*. 2017;18: 149–207.  
397 doi:10.1177/1529100618760521
- 398 12. Campbell JL, Quincy C, Osserman J, Pedersen OK. Coding In-depth Semistructured  
399 Interviews: Problems of Unitization and Intercoder Reliability and Agreement. *Sociological*  
400 *Methods & Research*. 2013;42: 294–320. doi:10.1177/0049124113500475
- 401 13. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. First Outbreak  
402 Response Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and  
403 Surveillance of Adverse Events, Guinea, 2012. *PLOS Neglected Tropical Diseases*.  
404 2013;7: e2465. doi:10.1371/journal.pntd.0002465
- 405 14. Massing LA, Aboubakar S, Blake A, Page A-L, Cohuet S, Ngandwe A, et al. Highly  
406 targeted cholera vaccination campaigns in urban setting are feasible: The experience in  
407 Kalemie, Democratic Republic of Congo. *PLOS Neglected Tropical Diseases*. 2018;12:  
408 e0006369. doi:10.1371/journal.pntd.0006369
- 409 15. Ngwa MC, Alemu W, Okudo I, Owili C, Ugochukwu U, Clement P, et al. The reactive  
410 vaccination campaign against cholera emergency in camps for internally displaced  
411 persons, Borno, Nigeria, 2017: a two-stage cluster survey. *BMJ Glob Health*. 2020;5:  
412 e002431. doi:10.1136/bmjgh-2020-002431

- 413 16. Peprah D, Palmer JJ, Rubin GJ, Abubakar A, Costa A, Martin S, et al. Perceptions of oral  
414 cholera vaccine and reasons for full, partial and non-acceptance during a humanitarian  
415 crisis in South Sudan. *Vaccine*. 2016;34: 3823–3827. doi:10.1016/j.vaccine.2016.05.038

416



medRxiv preprint doi: <https://doi.org/10.1101/2024.06.25.24309497>; this version posted June 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

from Brewer et al. [11]